Is improvement in comorbid major depression associated with longer survival in people with cancer? A long-term follow-up of participants in the SMaRT oncology-2 and 3 trials by Mulick, Amy et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Is improvement in comorbid major depression associated with
longer survival in people with cancer? A long-term follow-up of
participants in the SMaRT oncology-2 and 3 trials
Citation for published version:
Mulick, A, Walker, J, Puntis, S, Symeonides, S, Gourley, C, Burke, K, Wanat, M, Frost, C & Sharpe, M
2018, 'Is improvement in comorbid major depression associated with longer survival in people with cancer?
A long-term follow-up of participants in the SMaRT oncology-2 and 3 trials', Journal of Psychosomatic
Research. https://doi.org/10.1016/j.jpsychores.2018.11.008,
https://doi.org/10.1016/j.jpsychores.2018.11.008
Digital Object Identifier (DOI):
10.1016/j.jpsychores.2018.11.008
10.1016/j.jpsychores.2018.11.008
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Journal of Psychosomatic Research
Publisher Rights Statement:
This is a pre-copyedited, author-produced version of an article accepted for publication in Journal of
Psychosomatic Research following peer review. The version of record "Is improvement in comorbid major
depression associated with longer survival in people with cancer? A long-term follow-up of participants in the
SMaRT oncology-2 and 3 trials" is available online at: https://doi.org/10.1016/j.jpsychores.2018.11.008
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 02. Jan. 2020
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
Is improvement in comorbid major depression associated with longer survival in people with 
cancer? A long-term follow-up of participants in the SMaRT Oncology-2 and 3 trials 
 
Amy Mulick1, Jane Walker2, Stephen Puntis2, Stefan Symeonides3, Charlie Gourley3, Katy 
Burke2, Marta Wanat2, Chris Frost1, Michael Sharpe2,* michael.sharpe@psych.ox.ac.uk 
 
1Department of Medical Statistics, Faculty of Epidemiology and Population Health, London 
School of Hygiene and Tropical Medicine, London, UK 
2Psychological Medicine Research, University of Oxford Department of Psychiatry, 
Warneford Hospital, Oxford, UK 
3University of Edinburgh Cancer Research UK Centre, Western General Hospital, Edinburgh, 
UK 
 
*Corresponding author at: Psychological Medicine Research, University of Oxford 
Department of Psychiatry, Warneford Hospital, Oxford, OX3 7JX, UK. 
 
 
 
ABSTRACT 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
Objective 
There is evidence that patients with cancer have worse survival if they have comorbid major 
depression, but uncertainty whether a reduction in depression severity improves survival. 
We aimed to address this question. 
Methods  
We did a secondary analysis of data from participants in the SMaRT Oncology-2 and 3 trials 
of depression treatment in patients with cancer and comorbid major depression (total n= 
642). Participants’ data were analysed as cohorts, defined by treatment (usual care or 
Depression Care for People with Cancer, an intensive treatment programme, in both trials) 
and cancer prognosis (good or poor, in SMaRT Oncology-2 and 3 respectively). We 
measured change in depression severity from randomisation to 12 weeks using Symptom 
Checklist Depression Scale (SCL-20) scores and assessed survival by linked mortality data. 
We used Cox regression to estimate the effect of a one-unit decrease in SCL-20 score on 
survival, controlling for measured confounders.  
Results 
We found no evidence for an association between improvement in depression and survival 
in any of the four cohorts, after adjusting for age, sex, primary cancer, baseline cancer 
severity and baseline depression severity. Pooling the cohorts in a fixed-effects meta-
analysis yielded an estimated 7% reduction in the hazard of death per one-unit decrease in 
SCL-20 score. This finding was not statistically significant; the 95% confidence interval 
extended from a 26% decrease to an 18% increase in hazard of death. 
Conclusion 
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We found no evidence that reduction in severity of comorbid major depression is associated 
with longer survival in patients with cancer.  
 
KEYWORDS: Cancer; survival; depression; cohort study 
INTRODUCTION 
There is considerable interest in the relationship between psychological factors and survival 
in patients with cancer. A particularly important psychological factor to consider in relation 
to cancer is comorbid major depression. Major depression affects approximately 10% of 
patients with cancer and there is evidence that depressed patients have a worse survival 
than patients who are not depressed [1-4]. But does a reduction in the severity of this 
comorbid depression improve patient survival? The answer to this question is important, 
not only because it has implications for clinical care, but also because it may help us to 
elucidate whether the relationship between depression and worse survival in patients with 
cancer is a causal one, or merely an association. 
We currently have limited evidence about improvement in depression severity and survival 
in patients with cancer. We are not aware of any studies directly addressing this question. 
However, we have found three of potential relevance [5-7]. All three studies merely 
compared changes in depression symptom scores with survival, in samples of patients not 
selected for having comorbid major depression; two found some evidence for an association 
and one did not.  
The availability of data on participants in two previously published clinical trials, linked with 
their long-term survival data, provided us with a unique opportunity to study the 
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relationship between change in severity of depression and survival in patients with cancer 
and comorbid major depression. In both these trials (SMaRT Oncology-2  in good prognosis 
cancers and SMaRT Oncology-3 in lung cancer, a poor prognosis cancer), we found that an 
intensive depression treatment programme (Depression Care for People with Cancer, DCPC) 
was much more effective than usual care in reducing the severity of major depression [8, 9]. 
In a previously published follow-up analysis of these trials , we also found that participants’ 
treatment allocation (to DCPC or to usual care) in these trials had no significant effect on 
their survival, despite the large difference in their effectiveness in reducing severity of 
depression [10].  
In this paper, we aimed to address an additional and separate question: Does improvement 
in depression severity predict subsequent survival in patients with cancer and comorbid 
major depression? 
METHODS 
Design 
We analysed data from participants in two clinical trials (SMaRT oncology-2 and SMaRT 
oncology-3) that had been subsequently linked with long-term survival data. The trials were 
two-arm parallel group randomised controlled studies which compared a depression 
treatment programme called Depression Care for People with Cancer (DCPC) with usual care 
in patients with cancer and comorbid major depression. DCPC is a manualised, 
multicomponent (with both pharmacological and psychological components), collaborative 
care treatment that is delivered systematically by a team of cancer nurses and psychiatrists 
in collaboration with oncologists and primary care physicians  [11]. Usual care was provided 
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by the participants’ own primary care physician and oncology team. The trials were 
registered with Current Controlled Trials, numbers ISRCTN40568538 and ISRCTN75905964. 
 
We recruited a total of 642 participants to these two trials from three cancer centres in 
Scotland, UK and their associated clinics.  SMaRT oncology-2 recruited five hundred patients 
with good prognosis cancers (predicted survival ≥12 months estimated by their cancer 
specialist) and comorbid major depression between 12th May 2008 and 13th May 2011. 
SMaRT oncology 3 recruited one hundred and forty-two patients with lung cancer 
(predicted survival ≥3 months) and comorbid major depression between 5th January 2009 
and 9th September 2011.  
 
In both trials participants were randomly allocated (1:1) to either DCPC or usual care. DCPC 
was found to be highly effective in reducing depression severity. The trial methods, 
treatments and findings are described in detail in the relevant publications [8, 9, 12, 13].   
 
Because this analysis sought an association between change in depression severity and 
survival, rather than an association with treatment given and survival, we analysed the 
participant data in cohorts. As the association between change in depression severity and 
survival may differ with type of depression treatment and also with prognosis of the cancer, 
we created four separate cohorts from the four trial arms (two trials, each with two arms). 
The cohorts therefore comprised participants with: (a) good prognosis cancer (SMaRT 
Oncology-2) allocated to usual care (n=247); (b) poor prognosis cancer (SMaRT Oncology-3) 
allocated to usual care (n=74); (c) good prognosis cancer (SMaRT Oncology-2) allocated to 
DCPC (n=253); and (d) poor prognosis cancer (SMaRT Oncology-3) allocated to DCPC (n=68).  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
 
Measures  
Change in Depression Severity 
Depression severity was measured in the trials using the self-rated Symptom Checklist 
Depression Scale (SCL-20). This widely-used scale is derived from the longer SCL-90 scale 
[14]. There are two versions of the SCL-20; version B was used in the trials [15]. The SCL-20 
has 20 items, each of which is rated from 0 to 4. The overall SCL-20 score is an average of 
the 20 individual item scores and therefore also ranges from 0 to 4.  A one unit decrease in 
the overall score indicates a mean decrease of one level of severity across the 20 symptoms.  
The scale has been found to have good agreement with other commonly used measures of 
depression severity, such as the Patient Health Questionnaire-9 and the Hamilton 
Depression Rating Scale [16][17].  
 
For this analysis, we defined change in depression severity as the change in a participant’s 
SCL-20 score between baseline (trial randomisation) and 12-weeks post-randomisation. We 
chose this particular time interval to allow sufficient time from baseline for changes in 
depression to occur, whilst also minimising missing data from early deaths. We standardised 
changes in depression severity to take into account the actual date of follow-up (for 
example if a participant’s SCL-20 score was actually collected at 13 weeks after 
randomisation, the change was multiplied by 12/13).  
 
Survival 
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We obtained mortality data on trial participants (dates and causes of death) from the 
National Records of Scotland database. We did this by sending a minimal dataset (each 
participant’s trial number, name, date of birth, gender, Community Health Index number, 
postcode, and date of randomisation) securely to the Information Services Division of NHS 
Scotland for record linkage. We calculated survival from 12 weeks post-randomisation, 
censoring follow-up in participants who had left Scotland (at their date of emigration) or at 
the latest date that data were available (31st July, 2015). Our main outcome was death from 
any cause. We also did a sensitivity analysis restricted to deaths attributed to cancer.  
 
Ethical Approval 
The analysis of trial data including participants’ survival data was approved by the Scotland 
A Research Ethics Committee (08/MRE00/23; 08/MRE00/95) and the NHS Scotland Privacy 
Advisory Committee. At the time of trial enrolment, participants had given written consent 
for us to obtain follow-up information from their medical records.  
 
Statistical analysis 
We investigated the associations between changes in depression severity and subsequent 
survival using Cox proportional hazards regression models. We used two separate models to 
analyse the four cohorts; one for the two cohorts of patients with good prognosis cancers 
and the other for the two cohorts of patients with poor prognosis cancer. We did this 
because we considered that survival, and potentially the effects of confounders, may differ 
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with cancer prognosis. Associations were expressed as hazard ratios (HRs) for a one-unit 
decrease in SCL-20 score.  
We adjusted for possible confounders of the association between change in depression 
severity and survival within cohorts. In order to decide which factors to adjust for, we 
constructed a causal diagram (see Figure 1) making plausible assumptions about the 
potential confounders. Those we included were: age, sex, primary cancer, baseline cancer 
severity (measured using cancer disease status for SMaRT Oncology-2 participants and 
cancer stage and treatment intent variables for SMaRT-Oncology-3 participants), and 
baseline depression severity. The diagram highlights a “minimally sufficient” subset of 
adjustment covariates that we explicitly adjusted for in the Cox models [18, 19].  
In each model, we included interactions between treatment allocation and all of the 
“minimally sufficient” covariates, thereby allowing estimation of cohort-specific effects. If 
the assumptions made in the causal diagram are correct, the causal model approach is 
statistically more efficient than including all confounders in the analysis model, and is 
equally effective in controlling bias from all the potential confounders. 
 
[Figure 1 here] 
 
For illustration (and as a companion to our formal analysis treating change in depression 
severity as a continuous variable) we plotted adjusted Kaplan-Meier survival estimates for 
each of the four cohorts, according to change in depression severity dichotomised at the 
median change. To make the adjustments, we used the inverse probability weighting 
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method described by Cole and Hernan including the same set of covariates as in the Cox 
models [20]. We paired each Kaplan-Meier plot with a box-plot displaying the distribution of 
the changes in depression severity in the cohort and the median change.    
 
We pooled the hazard ratios obtained from the cohorts in stages: first, we combined the 
two usual care cohorts, then we combined the two DCPC cohorts and finally we combined 
all four cohorts. We did this after checking at each stage that there was no evidence of 
heterogeneity in the hazard ratios. We used this approach because we anticipated greater 
similarity in the effect of depression improvement on survival in the two cohorts which 
received DCPC (and correspondingly in the two usual care cohorts). This was because the 
DCPC cohorts had received an intervention that substantially reduced the severity of 
depression in many of the participants, and thereby offered greater ability to detect an 
association between change in depression severity and survival. The procedure we used was 
first to pool log hazard ratios (for a 1-unit change in SCL-20 scores) for the two usual care 
cohorts using the inverse variance method in a fixed-effects meta-analysis, and then to do 
the same for those from the two DCPC cohorts, testing for heterogeneity using a Wald test 
in each case. We then estimated an overall pooled log hazard ratio combining the results 
from the (pooled over trials) usual care and DCPC cohorts, again testing for heterogeneity 
using a Wald test.  We repeated the pooled analysis looking at only deaths attributed to 
cancer. 
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We performed all Cox regression analyses using Stata v15 (StataCorp, College Station, TX, 
USA) and the meta-analyses using the package “meta” in R v3.4.1. 
 
 
RESULTS 
In total 589/642 (92%) of the SMaRT Oncology-2 and 3 trial participants were included in 
the analysis. The remainder had either died (4% of the SMaRT Oncology-2 sample and 10% 
of the SMaRT Oncology-3 sample) or had missing depression severity data because of  loss 
to follow-up (an additional 4% of the SMaRT Oncology-2 sample and 11% of the SMaRT 
Oncology-3 sample) at the 12-week follow-up.  All participants included in the analysis had 
follow up data from 12 weeks post-randomisation (the time-point at which change in 
depression severity from randomisation was calculated) until their death, or until 31st July, 
2015 if that was sooner. The median duration of follow up for each cohort was as follows: 
Good prognosis cancer (SMaRT Oncology-2) and usual depression care 4.9 (IQR: 4.2, 5.5) 
years; poor prognosis cancer (SMaRT Oncology-3) and usual depression care 1.0 (IQR: 0.44, 
2.8) year; good prognosis cancers (SMaRT Oncology-2) and DCPC 4.1 (IQR: 4.8, 5.7) years; 
poor prognosis cancers (SMaRT Oncology-3) and DCPC 1.9 (IQR: 0.64, 4.2) years.   
 
Table 1 shows the demographic and clinical characteristics of the participants included in 
the analysis. Their mean age was 57.8 years and 85% were female. 
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[Table 1 here] 
 
Change in depression severity 
Table 1 and the boxplots in Figure 2 show that, in each of the four cohorts, the majority of 
participants reported improvement in depression severity, with the average change being 
markedly greater, and the standard deviation slightly larger, in the cohorts who had been 
allocated to DCPC. A small number of participants had a worsening of depression. 
 
[Figure 2 here] 
 
Survival  
112 of the participants (37%) in the usual care cohorts and 90 (31%) in the DCPC cohorts 
died during the follow-up period. The primary causes of death are shown in Table 2. Most of 
the deaths (174/202; 86%) were attributed to cancer and none to suicide. 
 
[Table 2 here] 
 
Association between change in depression severity and survival 
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We found no statistically significant associations between the change in depression severity 
and survival in any of the four cohorts. The HRs shown in Figure 3 estimate the effect of a 
one-unit decrease in SCL-20 score, from baseline to 12 weeks, on hazard of death, adjusted 
explicitly for baseline depression severity and baseline cancer severity, and implicitly for 
primary cancer, age, and sex. The associations between change in depression and survival 
are also illustrated in the adjusted Kaplan-Meier survival curves (Figure 2), where the red 
lines track the 50% of participants with the most depression improvement and blue lines the 
50% with the least (including the participants who worsened) in each cohort.  
 
[Figure 3 here] 
 
There was no evidence of heterogeneity in the hazard ratios seen in the two usual care 
cohorts (I2=0, p=0.54) or in the two DCPC cohorts (I2=0, p=0.66), we computed pooled 
estimates for both. There was also no evidence of associations between change in 
depression severity and survival in either the pooled usual care cohorts (p=0.30) or the 
pooled DCPC cohorts (p=0.88), and no evidence for heterogeneity in the hazard ratios 
(p=0.38). We therefore pooled all four cohorts.  
 
The pooled sample yielded an estimated overall 7% reduction in the hazard of death (0.93, 
95% C.I. 0.74 to 1.18) per unit decrease in SCL-20 at 12 weeks (I2=0, p=0.72). However, as 
can be seen in Figure 3, the wide confidence interval around this pooled estimate is 
consistent with both a moderate increase and a moderate decrease in survival. The final 
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pooled estimate was not sensitive to cause of death. We censored deaths that were not 
primarily caused by cancer and re-ran the analysis, but this had little effect on the result (HR 
0.94, 95% CI [0.73, 1.21]). 
 
DISCUSSION 
In this analysis of clinical trial data we found no statistically significant evidence for an 
association between an improvement in comorbid major depression and longer subsequent 
survival in people with cancer.  Whilst we did observe an estimated seven percent reduction 
in the hazard of death per unit decrease in SCL-20 depression severity score measured over 
12 weeks, when we pooled the four cohorts studied, the 95% confidence interval around 
this estimate extended from a 26% decrease to an 18% increase, indicating a range of 
associations from modest benefit to modest harm. Restricting the analysis to deaths 
attributed to cancer did not substantially alter this finding.  
The main strengths of the study were: First, all the participants had oncologist-diagnosed 
cancer and interview-diagnosed major depression. Furthermore, most participants had 
changes in the severity of their depression over the 12-week period used in the analysis. 
Second, the participants were divided into clearly defined cohorts according to both the 
treatment they had been allocated to and the prognosis of their cancer type as assessed at 
baseline. Third, the follow-up data on survival of participants were complete.  
The study also had limitations: First, the size of the cohorts available offered only limited 
power to detect potentially small effects of changes in depression severity on survival. 
Second, the participants were predominantly female and had a variety of cancer types, 
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potentially limiting the generalisability of the findings. Third, we only measured change in 
depression severity over a 12-week period; although substantial changes in depression 
severity were observed during this period. Fourth, we only assessed depression status up to 
12 weeks and are therefore unable to determine the cumulative exposure to depression 
that patients had between then and the time of their death. Fifth, we may not have been 
able to account for all the potential confounders of the association between depression 
change and survival, including changes in cancer status and cancer treatment given after 
assessment at baseline. Finally, although we were able to obtain long-term mortality data, 
we were not able to follow up all trial participants to the date of their death. Whilst this 
limitation makes us potentially unable to detect a longer-term effect of changes in 
depression severity on survival, it seems likely that the effect of a reduction in depression 
severity would manifest in the study period. 
Depression, particularly major depressive disorder, is an established risk factor for mortality 
in the general population [21]. Depression has also been found to predict worse survival in 
people suffering from a variety of medical conditions, including myocardial infarction, heart 
failure, diabetes and stroke, as well as in patients receiving renal dialysis and organ 
transplant [22-27]. Whilst the presence of depression has been found to predict worse 
subsequent survival in patients with a variety of cancers, the nature of the association has 
not been established.  
We are not aware of any other studies that have directly addressed the question. However, 
we have identified three previous studies with relevant findings: First, a cohort study of 
patients with lung cancer found that patients who had high baseline depressive symptom 
scores that reduced in severity between baseline and one year (n=156) survived longer than 
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those whose scores did not decrease [5]. Second, a secondary analysis of a trial of group 
psychotherapy in breast cancer patients (n=125) which had found no effect of treatment on 
survival, found an association between reduced depressive symptom scores (in the trial 
arms combined) and better survival [6]. Finally, a trial of early palliative care for patients 
with non-small cell lung cancer, found that palliative care improved survival, but a 
secondary analysis of the trial data did not find an association between survival and changes 
in depression severity [7]. Importantly, all three of these studies examined only the 
association of changes in score on depression questionnaires, not on the reduction in 
severity of diagnosed major depression. If a reduction in the severity of depression improves 
survival it would seem unlikely that such an effect would be found with small improvements 
in depression in a general sample of cancer patients but not with substantial reductions in 
depression in a sample of cancer patients with comorbid major depression. 
As far as we are aware, the current study is the first to seek evidence of an association 
between a change in depression severity and survival in patients with diagnoses of cancer 
and comorbid major depression. Our previous analysis using data from the same trials found 
that allocation to intensive depression treatment (DCPC) did not improve survival over usual 
care [10]. This study answers the related but separate question of whether improvement in 
depression is associated with longer subsequent survival. Despite a substantial 
improvement in depression severity in many of the SMaRT Oncology-2 and 3 trial 
participants, there was no good evidence of an association between this improvement in 
depression and increased survival, although the confidence intervals around the findings 
were wide and compatible with both a moderate increase and a moderate decrease in 
hazard of death. Future studies could be designed to examine potential differential 
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associations with different clusters of depressive symptoms and also possible threshold 
effects of substantial reductions in depression severity. 
 
Conclusion 
 
Major depression is a common and important problem in patients with cancer that is 
associated with both reduced quality of life and worse survival. In the SMaRT Oncology-2 
and 3 trials of depression treatment, we observed a strong effect of DCPC on depression 
and quality of life. However whilst comorbid major depression predicts poorer survival in 
cancer patients, we did not find that improvement in depression severity is associated with 
longer survival.  Despite this finding, the beneficial effect of treatment of depression on 
quality of life provides sufficient reason to make it an important part of cancer care [28]. 
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Table 1: Characteristics of participants included in the analysis 
 Allocated to usual depression care  Allocated to Depression Care for 
People with Cancer (DCPC) 
 Good prognosis 
cancers  
(SMaRT Oncology-
2) 
Poor prognosis 
cancers  
(SMaRT 
Oncology-3) 
Good prognosis 
cancers  
(SMaRT 
Oncology-2) 
Poor prognosis 
cancers  
(SMaRT 
Oncology-3) 
Number of patients included in 
analysis (% of total randomised to 
trial arm) 
 
241 (98%) 60 (81%) 235 (93%)  53 (78%) 
Demographic & clinical characteristics at 12 weeks post-randomisation 
Age, years (SD) 56.3 (10.3) 63.2 (8.5) 56.7 (10.0) 63.7 (9.0) 
Female sex, n (%) 217 (90) 38 (63) 210 (89) 37 (70) 
Primary cancer, n (%) 
Breast 
Genito-urinary 
Gynaecological  
Other (non-lung) 
Non-Small Cell  Lung Cancer 
Small Cell  Lung Cancer 
Other lung 
 
129 (54) 
14 (6) 
61 (25) 
37 (15) 
- 
- 
- 
 
- 
- 
- 
- 
38 (63) 
13 (22) 
9 (15) 
 
134 (57) 
13 (6) 
49 (21) 
39 (17) 
- 
- 
- 
 
- 
- 
- 
- 
33 (62) 
12 (23) 
8 (15) 
Cancer stage*, n (%) 
1 
2 
3 
4 
Limited 
Extensive 
Unknown 
 
- 
- 
- 
- 
- 
- 
- 
 
11 (18) 
8 (13) 
16 (27) 
9 (15) 
10 (17) 
3 (5) 
3 (5) 
 
- 
- 
- 
- 
- 
- 
- 
 
13 (25) 
9 (17) 
9 (17) 
9 (17) 
4 (8) 
8 (15) 
1 (2) 
Disease status*, n (%) 
Disease-free 
Local  
Metastatic 
 
194 (80) 
11 (5) 
36 (15) 
 
- 
- 
- 
 
194 (83) 
15 (6) 
26 (11) 
 
- 
- 
- 
Treatment intent*, n (%) 
Good prognosis, radical  
Poor prognosis, radical  
Poor prognosis, palliative 
 
- 
- 
- 
 
9 (15) 
27 (45) 
24 (40) 
 
- 
- 
- 
 
13 (25) 
18 (34) 
22 (42) 
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Mean SCL-20 score at 
randomisation (SD) 
2.11 (0.56) 1.99 (0.56) 2.13 (0.61) 1.95 (0.51) 
Mean SCL-20 12-week change 
(SD)* 
-0.35 (0.68) -0.40 (0.57) -0.96 (0.86) -0.90 (0.73) 
     
Survival outcomes following 12 weeks post-randomisation 
Deaths, n (%) 63 (26) 49 (82) 52 (22) 38 (72) 
Median follow-up time, years 
(IQR) 
4.9 (4.2, 5.5) 1.0 (0.4, 2.8) 4.8 (4.1, 5.7) 1.9 (0.6, 4.2) 
Death rate (n per 100 person 
years) 
5.9 46.4 5.0 29.8 
Participant characteristics at the beginning of the follow-up period for this study (12 weeks post trial 
randomisation) and their subsequent survival data. *actual change standardised to 12 weeks  
 
Table 2: Primary causes of death 
 
Primary cause of 
death 
Allocated to usual depression care Allocated to Depression Care for People with 
Cancer (DCPC) 
 
 
Good prognosis 
cancers 
(SMaRT  
Oncology-2) 
 
Poor prognosis 
cancers 
(SMaRT 
Oncology-3) 
Good prognosis 
cancers 
(SMaRT Oncology-2) 
Poor prognosis 
cancers 
(SMaRT  
Oncology-3) 
Cancer 59 (94) 41 (84) 42 (81) 32 (84) 
  Breast  27 (43) - 16 (31) - 
  Gynaecological  12 (19) - 12 (23) - 
  Genitourinary  6 (10) - 4 (8) - 
  Lung  3 (5) 39 (80) - 32 (84) 
  Other1 11 (17) 2 (4) 10 (19) - 
Cardiovascular 
disease2 
2 (3) 2 (4) 6 (12) 3 (8) 
Respiratory 
disease 
1 (2) 1 (2) 3 (6) 3 (8) 
Other3 1 (2) 5 (10) 1 (2) - 
Total deaths 63 49 52 38 
 
Data are n (%). 1 Haematological, upper gastrointestinal, colorectal, primary peritoneal, unspecified intestinal 
and cancer of multiple primary sites. 2Myocardial infarction, chronic ischaemic heart disease, cerebrovascular 
disease, cardiac failure. 3Obstructed inguinal hernia, sarcoidosis, acute pancreatitis, gastrointestinal 
haemorrhage, l iver disease, sepsis. 
 
Figure 1: Assumed causal pathways between change in depression severity and survival 
Figure 2: Change in depression severity and Kaplan-Meier survival estimates 
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Figure 3:  Forest plot showing hazard ratios (HRs) for a one-unit decrease in SCL-20 score after 12 weeks on 
all-cause mortality.  
 
Highlights 
? Comorbid depression has been found to predict survival in cancer 
? There is no evidence that Improvement in co-morbid major depression lengthens 
survival 
? The nature of the relationship between comorbid depression and survival remains 
uncertain 
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